PTIX

Protagenic Therapeutics, Inc. is a neuroactive biopharmaceutical company. The Company has approximately six drug candidates targeting stress-related and CNS disorders, including treatments for obesity and metabolic disorders. The Company's pipeline includes PT-00114 in Phase I/IIa and five preclinical assets including PHYX-001, cannabinoid-based compounds, and modified stilbenoid assets. The PHYX-001 is a potassium channel modulator with a mechanism similar to XEN1101 and BHV-7000. The Company's cannabinoid assets include multiple cannabinoid-based compounds with composition-of-matter IP; potential in CNS, cardiometabolic, and other indications. The Company's cannabinoid assets also include a molecule with potential in the obesity, metabolic dysfunction sector, where the GLP-1 agonists have become medications. Its modified stilbenoid assets include modified stilbenoid compounds with composition-of-matter IP and anticonvulsant activity in preclinical models.

Wall Street analysts forecast PTIX stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for PTIX is  USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Protagenic Therapeutics Inc revenue for the last quarter amounts to -1.11M USD, decreased % YoY.

Protagenic Therapeutics Inc. EPS for the last quarter amounts to -1395403.00 USD, decreased % YoY.

Protagenic Therapeutics Inc (PTIX) has 1 emplpoyees as of December 15 2025.

Today PTIX has the market capitalization of 3.19M USD.